As of June 17, 2025, PLx Pharma Inc (PLXP) reports a Net Margin of -561.95%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of PLx Pharma Inc's Net Margin
Over recent years, PLx Pharma Inc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2021-12-31 | -561.95% |
| 2020-12-31 | -50700.00% |
| 2019-12-31 | -3596.49% |
| 2018-12-31 | 120.00% |
| 2017-12-31 | -1967.95% |
This slight upward trend highlights how PLx Pharma Inc manages its overall profitability and cost control over time.
Comparing PLx Pharma Inc's Net Margin to Peers
To better understand PLx Pharma Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| PLx Pharma Inc (PLXP) | -561.95% |
| Oramed Pharmaceuticals Inc (ORMP) | 412.31% |
| Royalty Pharma PLC (RPRX) | 37.95% |
| Zoetis Inc (ZTS) | 26.86% |
| Merck & Co Inc (MRK) | 26.68% |
| Eli Lilly and Co (LLY) | 23.51% |
Compared to its competitors, PLx Pharma Inc's Net Margin is about average compared to peers, reflecting typical industry profitability.